Evidence map›Paper›PMID 38445651›Full record

Trial reportJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2024

Low-dose exogenous melatonin plus evening dim light and time in bed scheduling advances circadian phase irrespective of measured or estimated dim light melatonin onset time: preliminary findings.

Leslie M Swanson, Trevor de Sibour, Kelley DuBuc, Deirdre A Conroy, Greta B Raglan, Kate Lorang, Jennifer Zollars, Shelley Hershner, J Todd Arnedt, Helen J Burgess

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03715465 (The Clinical Utility of DLMO in the Treatment of Delayed Sleep-Wake Phase Disorder), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03715465 phase3completednot on this map

The Clinical Utility of DLMO in the Treatment of Delayed Sleep-Wake Phase Disorder: A Randomized Trial

TypeinterventionalSponsorUniversity of MichiganRan2019 to 2021Enrolled44ConditionsDelayed Sleep Phase SyndromeArmsMelatonin 0.5 MG, Dim Light Melatonin Onset (salivary)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Responsiveness of ThymoDreamFrontiers in sleep · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Leslie M SwansonDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Trevor de SibourMedical School, Medical College of Wisconsin, Milwaukee, Wisconsin.
Kelley DuBucDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Deirdre A ConroyDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Greta B RaglanDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Kate LorangDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Jennifer ZollarsMichigan Institute for Clinical & Health Research, University of Michigan, Ann Arbor, Michigan.
Shelley HershnerDepartment of Neurology, University of Michigan, Ann Arbor, Michigan.
J Todd ArnedtDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Helen J BurgessDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan.
University of Michigan–Ann Arbor · USMedical College of Wisconsin · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UM1TR004404 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Julie C Lumeng · 2023 to 2026
$39.8M
NCATS NIH HHS UM1 TR004404
6 · The paper itself

Abstract

STUDY

objectivesThe purpose of the present study was to preliminarily evaluate whether knowing the dim light melatonin onset (DLMO) time is advantageous when treating delayed sleep-wake phase disorder with low-dose melatonin treatment plus behavioral interventions (ie, evening dim light and time in bed scheduling).

methodsIn this randomized, controlled, double-blind trial, 40 adults with delayed sleep-wake phase disorder were randomly assigned to 4 weeks of 0.5 mg timed to be administered either 3 hours before the DLMO (measured DLMO group, n = 20) or 5 hours before sleep-onset time per actigraphy (estimated DLMO group, n = 20), in conjunction with behavioral interventions. The primary outcome was change in the DLMO (measured in-home). Secondary outcomes included sleep parameters per diary and actigraphy (sleep-onset and -offset times and total sleep time), Morningness-Eveningness Questionnaire, Multidimensional Fatigue Inventory, PROMIS-Sleep Disturbance, PROMIS-Sleep Related Impairment, and Pittsburgh Sleep Quality Index. Mixed-effects models tested for group differences in these outcome.

resultsAfter applying the Bonferroni correction for multiple comparisons (significant

conclusionsScheduled low-dose melatonin plus behavioral interventions may improve many circadian and sleep parameters regardless of whether melatonin administration is scheduled based on estimated or measured DLMO. A larger-scale trial is needed to confirm these preliminary findings. CLINICAL

trial registrationRegistry: ClinicalTrials.gov; Name: The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder; URL: https://clinicaltrials.gov/study/NCT03715465; Identifier: NCT03715465. CITATION: Swanson LM, de Sibour T, DuBuc K, et al. Low-dose exogenous melatonin plus evening dim light and time in bed scheduling advances circadian phase irrespective of measured or estimated dim light melatonin onset time: preliminary findings.

Indexed as

ActigraphyMelatoninSleep Disorders, Circadian RhythmAdultCircadian RhythmDouble-Blind MethodFemaleHumansMaleMiddle AgedSurveys and QuestionnairesTime FactorsTreatment OutcomeMelatonincircadian rhythmsdelayed sleep-wake phase disorderdim light melatonin onsetmelatonin

Identifiers

PMID38445651
PMCPMC11217625
OpenAlexW4392502303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.